Clinical study of Dendritic Cell Vaccine in patients with Gastroenterological Cancer and Hepato-Biliary-Pancreatic Cancer.

Clinical study of Dendritic Cell Vaccine in patients with Gastroenterological Cancer and Hepato-Biliary-Pancreatic Cancer. - Dendritic Cell Vaccine for GI & HBP cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005820

Enrollment

100

Registered

2011-06-22

Start date

2001-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer, Stomach cancer, Colon cancer, HCC, ICC, Bile duct cancer, pancreatic cancer

Interventions

Injection of tumor-lysate pulsed dendritic cell vaccine in patients with advanced GI &amp

HBP cancer. Injection of MUC1-peptide pulsed dendric cell vaccine in patients with advanced GI &amp

HBP cancer. Postoperative injection of tumor-lysate pulsed dendritic cell vaccine in patients with HCC. Postoperative injection of tumor-lysate pulsed dendritic cell vaccine in patients with ICC.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Clinically or pathologically diagnosed cancer 2.Age between 20 to 80 3.No severe organ function impairment 4.Written informed consent of the patient 5.Performance Status 0-2

Exclusion criteria

Exclusion criteria: 1.Pregnancy or lactation 2.Decision of unsuitableness by principal investigator 3.Patient with severe underlying disease 4.Patient with severe allergy disease

Design outcomes

Primary

Measure	Time frame
Clinical response Disease free survival Overall survival	—

Secondary

Measure	Time frame
Immunological response	—

Countries

Japan

Contacts

Public ContactAtsushi Aruga

Tokyo Women's Medical University Institute of Advanced Biomedial Engineering and Science

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026